Lux Capital

Fundraising isn’t success—not on its own. But this is a nice accomplishment for our team at Nomic Bio, made possible by their fearless execution over the past few years. I’m super grateful to all the Nomicists who have rallied around our mission to help scientists extend lives. There’s a lot of exciting technology being built in the worlds of biology, AI, and healthcare today. But we may not get as far without large-scale, clinically-relevant proteomic datasets acquired using tools that are accessible enough for broad adoption and versatile enough for end-to-end deployment. That’s what we’re building at Nomic, and this raise brings us one step closer. Big thanks to our users and partners—the scientific teams that have collectively profiled >400k samples using our nELISA to drive their R&D forward. Your relentless drive to improve patient outcomes and the bold (sometimes wild) ideas you bring to tackling disease inspire us every day. It truly takes a village to build this thing. Big thanks to our investors—past and present—for seeing Nomic’s vision and supporting us along the way. Special thanks to the folks at Lux Capital, Amplitude Ventures, AVANT BIO, Real Ventures, and SR One Capital Management. We’re hiring world-changers across the board: https://lnkd.in/eUx6juwH. Join us!

Ready to push the boundaries of science? Enveda is offering two exciting challenges for the Bio x ML hackathon we're co-hosting with our friends at Lux Capital and EvolutionaryScale: 1?? Enhancing MS/MS Fragmentation Predictions: Leverage our GrAFF-MS model, which uses graph neural networks to predict mass spectrometry fragmentation patterns, or develop your own solution. You'll have access to ~1 million curated MS/MS spectra. 2?? Advancing Molecular Similarity: Develop models that classify molecular similarity, capturing the nuanced perspective of expert chemists. Train your model on larger datasets and fine-tune it with Enveda's curated set of 600 molecular pairs, each annotated by five chemists. ?? Prize: $10,000 for the best team, plus the opportunity to present your work to, and work with, Enveda’s team. ?? Open to participants worldwide. More info here: https://lnkd.in/ek7Z6zRV Join the hackathon and make an impact: https://hackathon.bio/

We're officially welcoming Shaquille Vayda, Principal at Lux Capital, to Creyon's Board of Directors! Shaq's diverse experience spanning technology, aerospace and life sciences, with a focus on discovery and delivery platforms, synthetic biology and data infrastructure, aligns well with our innovative approach to drug engineering. https://lnkd.in/e6-X4965 #BiotechLeadership #AIinDrugDiscovery

?? Funding announcement! ?? Proud to co-lead Sakana AI's over $100M Series A with New Enterprise Associates (NEA) and Khosla Ventures! Sakana AI is pioneering nature-inspired AI, and we're excited to support their new collaboration with NVIDIA on AI research and infrastructure in Japan ?? ?? https://lnkd.in/dPhFENRt

?? Funding announcement! ?? We're thrilled to lead eGenesis, Inc. $191M Series D round, accelerating their groundbreaking work in kidney transplants. A major step toward transforming organ transplantation! #biotech #xenotransplantation More here: https://lnkd.in/dU6QT-3E

Inspired by Lux Capital, EvolutionaryScale, and Enveda Biosciences's second annual Bio x ML Hackathon, powered by Amazon Web Services (AWS). Once again, this Hackathon will bring together the top minds in science and AI to advance human health, progress knowledge, and uncover solutions to challenging, unsolved problems in biology... Apply by Sept 22nd! https://hackathon.bio/ Thanks to: Tracie Rotter Eric Zimmerman Tess van Stekelenburg Matthew Nemeth #AWSstartups #innovation #advancinghumanhealth ?? ? ??

We're back! Lux Capital is running a Bio x ML Hackathon with EvolutionaryScale and Enveda Biosciences Bio from Oct 10-20! By bringing together the world’s top minds, we’re driving forward the next frontier of science with AI-driven tools and scientific imagination. Build on top of the latest foundation models like ESM3 (98B parameters, GPU access) and proprietary datasets to predict protein activity, model across therapeutic modalities, and develop next-gen biology applications. Model APIs, datasets & compute powered by Amazon Web Services (AWS), OpenAI, NVIDIA, DigitalOcean, EvolutionaryScale, Modal, LatchBio, Together AI, Enveda Biosciences, and RunPod. Open globally. Get started here: hackathon.bio

Why have algorithms not upended venture capital? Dario Soatto explains in his first column for the Riskgaming newsletter:

Co-founder and Managing Partner of Lux Capital Josh Wolfe is a master at understanding complex, emerging technologies. In our conversation, Josh shared how he identifies the next big thing, his contrarian views on nuclear energy, biotech, and robotics, as well as his thoughts on the state of the venture capital market today. Here are some key takeaways: → Obsessions Fuel Breakthroughs Josh often dives deep into a particular technology for many weeks, even years, juggling 10-12 of these obsessions at once. For example, his decade-long focus on using technology to replicate and understand smells seemed fruitless for years until the right technological breakthrough occurred. When you believe something is inevitable but aren’t sure of the timeline, continuing to pursue an idea can eventually lead to big rewards when timing and technology align. → How Josh Masters New Domains Josh dives deep into scientific research (not just page one) to quickly become knowledgeable in new fields, and he connects with top scientists to learn about breakthroughs before they’re public. By the time he talks to experts, he’s already well-informed, allowing him to spot trends early and make investment decisions off the beaten path. For example, when the venture world was fixated on solar, wind, and biofuels, Josh turned his attention to his well-informed thesis on nuclear energy. → De-Risking Investments to Maximize Returns Josh Wolfe emphasizes the importance of de-risking early investments by identifying key risks to the business and providing resources to mitigate them. Later investors will then be willing to pay a higher price because they face less uncertainty. His approach is not about being contrarian for its own sake, but about being ahead of the curve (much like moving to Brooklyn before it became mainstream). You want others to agree with you, just later. → Josh’s Harsh Take on the Future of VC Josh predicts that 30-50% of venture firms may not survive the next few years, particularly those that are unable to adapt to changing market dynamics. Josh believes the firms that will thrive are those that can be nimble, make smart capital allocations, and avoid the pitfalls that come from following the herd in overhyped sectors. More insights for anyone in tech or venture capital in the full episode: https://lnkd.in/dgxR4fMr

Lux MBA summer intern Bradley Aka shared his thoughts on digital twins and how they can be implemented to transform healthcare in his latest piece below. Check it out:https://lnkd.in/eazMG3nf